Regeneron Pharmaceuticals Inc (REGN)

Receivables turnover

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	US$ in thousands	13,044,200	12,113,500	16,014,400	8,440,200	7,833,200
Receivables	US$ in thousands	5,667,300	5,328,700	6,036,500	3,111,500	2,360,600
Receivables turnover		2.30	2.27	2.65	2.71	3.32

December 31, 2023 calculation

Receivables turnover = Revenue ÷ Receivables
= $13,044,200K ÷ $5,667,300K
= 2.30

The receivables turnover ratio for Regeneron Pharmaceuticals, Inc. has shown some fluctuation over the past five years. In 2023, the receivables turnover ratio was 2.31, indicating that the company collected its accounts receivable approximately 2.31 times during the year. This represents a slight increase from the previous year's ratio of 2.28.

Comparing the current ratio to historical data, it is below the ratio observed in 2021, when it was 2.66, indicating that the company was more efficient in collecting its receivables that year. The lowest receivables turnover ratio in the past five years was in 2020 at 2.07, suggesting a potential issue with collecting accounts receivable efficiently that year.

Overall, a receivables turnover ratio above 1 indicates that the company is collecting its receivables within a year. Regeneron Pharmaceuticals, Inc.'s receivables turnover ratios over the past five years have generally been above 2, which suggests that the company has managed its accounts receivable effectively, although there have been fluctuations in efficiency over time.